Abstract
BackgroundAfter failure of a first anti-TNF agent (aTNF), clinicians may choose to prescribe an alternative aTNF or switch to a ‘non-aTNF biologic antirheumatic agent’ (non-aTNF-BI: abatacept, tocilizumab or rituximab (RTX))....
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have